ACCC | FDA Approves Trastuzumab and Hyaluronidase-oysk for Breast Cancer
FDA Approves Trastuzumab and Hyaluronidase-oysk for Breast Cancer
On February 28, the Food and Drug Administration approved trastuzumab and hyaluronidase-oysk injection for subcutaneous use (Herceptin Hylecta, Genentech Inc.) for the treatment of HER2-overexpressing breast cancer.
In Person Conference & ConventionOctober 3, 2026 at 7:30 AM EDT8787 Keystone Crossing, Indianapolis, IN, USASheraton Indianapolis Hotel at Keystone Crossing, Indianapolis
In Person Conference & ConventionOctober 15, 2026 at 5:30 PM PDT255 N Virginia St, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton, Reno
